Sitagliptin

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Sitagliptin Phosphate (50 mg, 100 mg) is an orally active, highly selective beta-amino acid-derived dipeptidyl peptidase-4 (DPP-4) inhibitor on the WHO Model List of Essential Medicines. It competitive inhibits DPP-4, preventing the rapid enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), prolonging postprandial active incretin levels. This stimulates glucose-dependent insulin secretion and suppresses postprandial glucagon secretion without causing hypoglycemia or weight gain. Indicated for type 2 diabetes mellitus as monotherapy or combination therapy.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Glimepiride is a cornerstone dual-action antidiabetic combination on the WHO Model List of Essential Medicines. Metformin acts as an insulin-sensitizing biguanide that reduces excessive hepatic glucose output and improves peripheral glucose uptake without causing hypoglycemia or weight gain, while glimepiride acts as an insulin secretagogue, binding to SUR1 receptors on pancreatic beta-cell membranes to stimulate physiological postprandial insulin release. Indicated as an adjunct to diet and exercise in type 2 diabetes mellitus inadequately controlled by metformin alone.

Metformin Hydrochloride and Sitagliptin is a landmark incretin-based dual antidiabetic combination on the WHO Model List of Essential Medicines. Sitagliptin selectively inhibits DPP-4, elevating active GLP-1 and GIP to enhance glucose-dependent insulin synthesis and suppress postprandial glucagon, while metformin addresses insulin resistance and decreases hepatic glucose production. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.